CoChat

Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease

Open access
Summarell, Carly C Ginter, Sheehan, Vivien A · 2016 · Experimental Biology and Medicine

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Hydroxyurea is an excellent therapeutic agent for the pharmacological induction of HbF in patients with sickle cell disease (SCD). However, all completed clinical trials of hydroxyurea have excluded patients with hemoglobin SC (HbSC) disease. HbSC differs significantly in pathophysiology from HbSS, as HbC does not sickle, but instead causes cellular dehydration which potentiates sickling of HbS. Many severely affected HbSC patients have been placed on hydroxyurea on a case by case basis, but there are no large scale prospective data on safety or efficacy of hydroxyurea in this subset of patients with SCD. Here, we report a case series of 14 pediatric patients with HbSC treated to maximum tolerated dose (MTD) with hydroxyurea. Those who failed to show clinical improvement after at least six months at MTD were offered phlebotomy in addition to hydroxyurea. Five out of 11 patients with HbSC who achieved MTD failed to demonstrate clinical improvement on hydroxyurea. Of the four placed on dual hydroxyurea and phlebotomy therapy, all showed at least partial clinical improvement. Percent dense red blood cells (%DRBC) were measured via an ADVIA hematology analyzer. A marked rise in percent dense cells preceded clinical complications in three patients. Dual therapy with hydroxyurea and phlebotomy may be an effective approach to patients with HbSC that do not experience improvement with hydroxyurea alone. Monitoring of %DRBC may predict adverse events and aid in assessing hydroxyurea compliance. Large scale clinical trials are needed to evaluate the safety and efficacy of hydroxyurea and hydroxyurea with phlebotomy in patients with HbSC disease.

Overview

Integrity signals

Registry

Crossref · 10.1177/1535370216639737

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 19

Metadata

Authors
Summarell, C. C. G., & Sheehan, V. A.
Affiliations
Baylor College of Medicine (US)
Corresponding author
Sheehan, Vivien A
Venue
Experimental Biology and Medicine
Published
2016-03-17
Volume
241
Issue
7
Pages
737-744
ISSN
  • 0071-3384 (ISSN-L)
  • 1535-3702
  • 1535-3699
OpenAlex
W2341094018
Cited by
17
References
26
Citations by year
2026: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2018: 1 · 2016: 4
FWCI
1.21
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Experimental Biology and Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (K08DK110448)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
Keywords
hemoglobin SC disease, hydroxyurea, phlebotomy, sickle cell disease, fetal hemoglobin induction, pediatric patients, maximum tolerated dose, treatment failure, adverse event prediction
MeSH terms
Antisickling Agents, Child, Combined Modality Therapy, Female, Hemoglobin SC Disease, Humans, Hydroxyurea, Male, Phlebotomy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease. https://app.cochat.ai/papers/10.1177/1535370216639737
The paper
Summarell, C. C. G., & Sheehan, V. A. (2016). Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease. Experimental Biology and Medicine. https://doi.org/10.1177/1535370216639737

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.